People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intellipharmaceutics International Inc. | — | Pharmaceuticals | Series A | $17.5M | $31.4M | 2018 |
Andrew Patient at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Patient on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eldon R. Smith | 1 | 3 |
| Eldon Smith | 1 | 2 |
| Bahadur R. Madhani | 1 | 1 |
| Shameze N. Rampertab | 1 | 1 |
| Amina Odidi | 1 | 1 |
| Isa Odidi | 1 | 1 |
| Kenneth R. Keirstead | 1 | 1 |
| Kenneth Keirstead | 1 | 1 |
| Bahadur Madhani | 1 | 1 |
| Michael R. Campbell | 1 | 1 |
| John N. Allport | 1 | 1 |
| Andrew R. Patient | 1 | 1 |
| Patrick N. Yat | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.